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Table 1 – Characteristics of the patients.
Ribavirin treated Not treated
Age (mean) 11.6 7.3
Gender (female) 17 5
Time to healing 8.9 7.8
Duration of fever 5.3 4.7
Need for erythrocyte transfusion 8 1
Need for FFP transfusion 11 1
Duration for hospitalization 5.9 4.2Crimean-Congo hemorrhagic fever (CCHF) is a severe, often
potentially fatal disease in humans, caused by infection with
CCHF virus (CCHFV) belonging to the genus Nairovirus of the
Bunyaviridae family. The current approach to treatment of
CCHF is based on supporting hematologic and coagulation
status of the patient, with replacement of cells and factors
as needed, but use of ribavirin is controversial. In this study
it was aimed to evaluate and compare outcomes of pediatric
patients receiving or not receiving ribavirin.
The study included patients younger than 18 years of age
admitted to Ankara Hematology Oncology Children’s Training
and Research Hospital between January, 2009, and November,
2014, with fever, bleeding, leukopenia, and/or thrombocy-
topenia with positive IgM and/or PCR results for CCHFV in
blood. Physical ﬁndings and the laboratory tests were included
in data analysis.
Out of 46 pediatric patients (18 female, 28 male), aged
between 1 and 17 years (mean: 10.1 ± 4.8 years) with CCHF,
30 patients were treated with ribavirin, characteristics of the
patients are presented in Table 1.
Diagnosis of CCHF was conﬁrmed by PCR in 32 (69.6%)
patients, by serology in 16 (42.1%) patients, both serology and
PCR in 2 patients. On admission anemia was present in 11
(23.9%) patients, leukocytopenia in 39 (84.8%) patients, throm-
bocytopenia in 40 (86.9%) patients. Elevated AST, ALT, LDH, and
CPK levels were present in 38 (82.6%), 35 (76.1%), 40 (87%), 25
(54.3%) patients, respectively.
The length of stay in hospital ranged from 1 to 14 days
(mean: 5.4 ± 3.02 days). No fatal cases were observed. In
patients treated with ribavirin, duration of therapy ranged
from 3 to 10 days (mean: 8.7 ± 2.01 days).
The only currently used antiviral drug in CCHF is ribavirin;
however, its efﬁcacy is a matter of concern as randomized
controlled trials are lacking. In our study both groups treated
and not treated with ribavirin presented no fatal cases. Also
in ribavirin treated group need for erythrocyte and plasma
transfusion was more  frequent and duration of fever and
hospitalization were longer in ribavirin treated group butthis could have been due to ribavirin use in more  severe
patients.
In our previous study we  showed that Turkish pediatric
patients had a milder course of CCHF,1 which might be due to
a lower cytokine response in pediatric cases. Lower cytokine
levels in pediatric patients in could be a good prognostic factor
for a favorable outcome.2
One randomized controlled trial evaluating the efﬁcacy of
ribavirin performed in
Turkey, compared 64 patients who received ribavirin and
72 who did not showed no signiﬁcant difference in mortality,
proportion of patients requiring platelet transfusion, length of
hospital stay, recovery time, or laboratory parameters.3 How-
ever, that study included late cases and ribavirin might not be
beneﬁcial in late stages of the disease. Side effects of ribavirin
are the major obstacle, such as bradycardia, genotoxicity, and
mutagenicity.4–7
As the use of ribavirin in CCHF is still controversial8,9 more
data are warranted to reach a deﬁnitive conclusion.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.











1413-8670/© 2016 Elsevier Editora Ltda. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).b r a z j i n f e c t d i s .
 e  f  e  r  e  n  c  e  s
. Kızılgun M, Ozkaya-Parlakay A, Tezer H, et al. Evaluation of
Crimean-Congo hemorrhagic fever virus infection in children.
Vector Borne Zoonotic Dis. 2013;13(11):804–6,
http://dx.doi.org/10.1089/vbz.2013.1297.
.  Tezer H, Ozkaya-Parlakay A, Kizilgün M, et al. Cytokine
concentrations in pediatric patients with Crimean-Congo
hemorrhagic fever. Pediatr Infect Dis J. 2014;33(11):1185–7,
http://dx.doi.org/10.1097/INF.0000000000000398.
.  Koksal I, Yilmaz G, Aksoy F, et al. The efﬁcacy of ribavirin in the
treatment of Crimean-Congo haemorrhagic fever in Eastern
Black Sea region in Turkey. J Clin Virol. 2010;47:
65–8.
. Tezer H, Ozkaya Parlakay A, Gülhan B, Cetin I. Bradycardia
related to ribavirin in four pediatric patients with
Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis.
2014;14(6):464–5, http://dx.doi.org/10.1089/vbz.2012.1294.
. Tatar A, Ozkurt Z, Kiki I. Genotoxic effect of ribavirin in
patients with CrimeanCongo hemorrhagic fever. Jpn J Infect
Dis. 2005;58:313–5.
. D’Souza UJ, Narayana K. Mechanism of cytotoxicity of ribavirin
in  the rat bone marrow and testis. Indian J Physiol Pharmacol.
2002;46:468–74.
. Narayana K, D’Souza UJ, Seetharama Rao KP. Ribavirin-induced
sperm shape abnormalities in Wistar rat. Mutat Res.
2002;513:193–6.
]. Ergonul O. Evidence supports ribavirin use in Crimean-Congo
hemorrhagic fever. Int J Infect Dis. 2014;29:296,
http://dx.doi.org/10.1016/j.ijid.2014.08.016.6;2 0(2):222–223 223
. Ceylan B, Turhan V. The efﬁcacy of ribavirin in Crimean-Congo
hemorrhagicfever-randomized trials are urgently needed. Int J
Infect Dis. 2014;29:297–8,
http://dx.doi.org/10.1016/j.ijid.2014.08.015.
Hasan Tezera, Aslinur Ozkaya-Parlakayb,∗, Belgin Gulhanb,
Saliha Kanik-Yuksekb
a Gazi University School of Medicine, Department of Pediatric Infec-
tious Diseases, Ankara, Turkey
b Ankara Hematology and Oncology Research Hospital Pediatric
Infectious Diseases Unit, Ankara, Turkey
∗ Corresponding author at:  Ankara Hematology and Oncology
Research Hospital Pediatric Infectious Diseases Unit Dıskapı,
06110 Ankara, Turkey.
E-mail address: aslinur.o@gmail.com (A. Ozkaya-Parlakay).
Received 2 November 2015
Accepted 12 November 2015
Available online 2 February 2016http://dx.doi.org/10.1016/j.bjid.2015.11.012
